



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


# PRODUCT INFORMATION



## Besifovir

Item No. 37570

**CAS Registry No.:** 441785-25-7  
**Formal Name:** P-[[[1-[(2-amino-9H-purin-9-yl)methyl]cyclopropyl]oxy]methyl]-phosphonic acid  
**Synonym:** BFV  
**MF:** C<sub>10</sub>H<sub>14</sub>N<sub>5</sub>O<sub>4</sub>P  
**FW:** 299.2  
**Purity:** ≥95%  
**UV/Vis.:** λ<sub>max</sub>: 226 nm  
**Supplied as:** A solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Besifovir is supplied as a solid. A stock solution may be made by dissolving the besifovir in the solvent of choice, which should be purged with an inert gas. Besifovir is soluble in the organic solvent DMSO.

### Description

Besifovir is an antiviral nucleoside derivative of 2'-deoxyguanosine 5'-monophosphate (dGMP; Item No. 16408).<sup>1</sup> It reduces viral replication in Huh7 cells infected with wild-type hepatitis B virus (HBV) or a lamivudine-resistant HBV clinical isolate (IC<sub>50</sub>s = 3.5 and 7.47 μM, respectively). Besifovir also reduces viral replication in Huh7 cells infected with an entecavir-resistant HBV clinical isolate (IC<sub>50</sub> = 26 μM).

### Reference

1. Won, J., Lee, A.R., Dezhbord, M., *et al.* Susceptibility of drug resistant hepatitis B virus mutants to besifovir. *Biomedicines* **10**(7), 1637 (2022).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 05/15/2023

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM